Introduction
============

Chagas' disease or American Trypanosomiasis represents a serious burden for millions of people worldwide. This parasitic infection, considered a neglected reemerging tropical disease, causes more than 10,000 deaths each year, being a main cause of heart failure in Latin America, where it is endemic ([@B41]). However, Chagas disease is currently expanding to non-endemic countries (United States and Canada) and continents (Europe, Asia, and Oceania) due to migration of infected people ([@B123]), affecting nearly 6 million people worldwide ([@B154]).

*Trypanosoma cruzi*, the etiological agent of Chagas disease, exhibits a variety of mechanisms to evade the host immune response. These mechanisms enable the parasite to establish an infection and persist in the host, determining a chronic stage ([@B45]). The *T. cruzi* life-cycle is extremely complex, involving an invertebrate hematophagous triatomine vector and an extensive range of mammalian hosts, including humans ([@B21]). *T. cruzi* metacyclic trypomastigotes, one of the infective forms of the parasite, are released in the feces or urine of triatomines after a blood meal. These infective forms encounter mucosa or discontinuous regions of the epithelium, infecting mammalian host cells ([@B16]). To invade these cells, trypomastigotes use a variety of virulence factors that interact with host components to help the parasite to invade mammalian cells. In trypomastigotes, gp90 ([@B32]; [@B156]), mucins ([@B148]; [@B157]), Tc85, trans-sialidase family (gp85, gp82 and TSA-1) ([@B27]), gp35/50 ([@B141]), TS ([@B112]), gp83 ([@B87]; [@B149]); penetrin ([@B107]); and proteases such as cruzipain, oligopeptidase B and Tc80 ([@B101]), have been described. Additionally, we have shown that *T. cruzi* calreticulin (TcCRT) is an important virulence factor on the *T. cruzi* surface ([@B115]).

In the host cell, trypomastigotes are confined in a parasitophorous vacuole, from which they escape to differentiate into amastigotes, the replicative form of the parasite in mammalian cells. After several rounds of replication, the amastigotes differentiate into another infective form of the parasite, the bloodstream trypomastigotes, which are released upon rupture of the host cell membrane and infect neighboring cells or enter the bloodstream ([@B16]). Long-term persistence likely involves episodic reinvasion as well as continuous infection that extends to different tissues ([@B84]). Once the trypomastigotes reach the bloodstream, the parasite bypasses the complement system mediated lysis and opsonization, with the support of surface proteins ([@B16]) or by capturing host plasma molecules ([@B108]). Thus, the parasite disseminates through the bloodstream to many tissues during the acute phase that may veer toward a chronic phase. During this stage, about 30% of those infected will develop symptoms of this disease ([@B16]).

*Trypanosoma cruzi* infection activates both innate and adaptive immune responses during the acute phase. These responses involve complement system activation, macrophages, natural killer cells, B cells, CD4^+^ and CD8^+^ T cell activation, as well as the production of pro-inflammatory cytokines such as interferon-gamma, tumor necrosis factor, interleukin-12 and interleukin-17 ([@B28]). Despite its activation, the immune response fails to completely eliminate the parasite, because *T. cruzi* has acquired a variety of strategies to evade the host immune response. Thus, trypomastigotes possess membrane-bound proteins that provide them with a certain degree of resistance to the complement-mediated lysis, enabling them to survive for longer periods in the bloodstream ([@B144]). Early studies have demonstrated that trypomastigotes are highly complement resistant, while non-infective epimastigotes are highly susceptible ([@B100]; [@B120]). This strategy to resist the complement system activation could be extremely important to define the evolutionary spectrum of possible hosts. Thus, birds are refractory to *T. cruzi* infection ([@B96]; [@B140]). After inoculation, parasites cannot be recovered from bird blood ([@B139]). However, parasites inoculated to fertile chicken eggs infect embryo cells until the 10th day post-fertilization ([@B102]). Thus, the elimination of the parasite could depend, in an important part, on the innate immune system and its maturation. Other studies indicate that metacyclic trypomastigotes are lysed by avian serum ([@B86]), in an antibody-independent manner ([@B72]). The administration of normal chicken serum to *T. cruzi* infected mice generates a marked decrease in their parasitemias ([@B73]). These results indicate that, in addition to the maturation of the immune response, the avian serum and its complement system destroy the parasite. However, the molecules and mechanisms involved are unknown.

Complement System Regulation in Pathogen Resistance to Complement
=================================================================

The complement system consists of about 40 proteins circulating in the blood/plasma or anchored to cell surfaces. This system is an important component of innate immune response which recognizes microbial pathogens, promoting opsonization, inflammation, clearance of immune complexes and cellular lysis ([@B70]). The complement system recognizes different patterns on the aggressors or antibodies bound to pathogenic antigens. Three different complement system activation pathways have been identified: Classical (CP), activated by antigen:antibody complexes and other molecular patterns which are recognized by C1q sometimes in conjunction with adaptor molecules, such as C-reactive protein ([@B65]); Lectins (LP), which responds to mannose containing polysaccharides through the collectin Mannan Binding Lectin (MBL), and to other targets such as acetyl sugars via the Ficolins and other Collectins such as CL-11 ([@B50]); AP, activated by a variety of microbial surfaces ([@B69]). The activation of these three pathways concludes the formation of C3 and C5 convertase enzymes ([@B150],[@B151]), and generation of opsonins C3b and C4b ([@B69]). In the CP, C1s, in the context of C1, a complex of three proteins C1q, C1r, C1s, is activated by binding of C1q to a target. C1s, a protease, will cleave both C4 and C2, forming the cell surface- bound C3 convertase (C4b,2b) that will activate C3, generating C3a and C3b fragments. C3b, similar to C4b, has a highly reactive thiolester bond that mediates binding to a nearby C4b,2b, thus initiating the assembly of C5-convertases (C4b,2b,3b), which cleaves C5 to generate C5a and C5b ([@B150],[@B151]; [@B69]). In the C5-convertas both C4 and C3 are covalently bound to the target membrane. Then, C5b associates with C6 and C7 in the fluid-phase (plasma), resulting in the C5b-7 complex, which inserts into the membranes of target cells where it binds to C8 and C9, forming a MAC. This step from C5-C9 is also named the TP ([@B71]). This MAC complex promotes membrane disruption and cell lysis ([@B150],[@B151]; [@B69]). In the LP, the danger recognition lectin modules, Ficolins and MBL, will recognize a variety of pathogen associated molecular patterns (PAMPS or danger signals), with subsequent activation of their serine proteases (MASPs). The following activation steps are similar to those of the CP. The AP is activated by default, detecting the lack of certain molecules (e.g., sialic acid) that are prominent on the host cell surface. C3 (C3bBb) and C5 (C3bBbC3b)-convertases are generated. Given the structural similarities that exist between C3 and C4, and between C2 and factor B, the AP and CP convertases share extensive properties such as the capacity to cleave C3 and C5. The steps and molecules involved in the TP are common to all activation routes.

The complement system is tightly controlled by regulatory proteins present in plasma and on the cell membranes ([@B99]), including those of selected pathogens. Thus, the CP is regulated by C1-INH, a serine protease inhibitor in plasma that binds activated C1, removing C1r and C1s from the complex and inactivating them ([@B30], [@B31]). The AP downregulation is provided by FI, a serine protease that cleaves C3b in the convertases ([@B99]). In fluid-phase, there are two proteins acting as cofactors for FI: FH and C4BP ([@B147]). Both break up convertases, a property termed "*decay acceleration"* ([@B52]; [@B117]). On membranes, decay-accelerating factor protein (DAF) binds to and disassemble the CP and AP convertases. The membrane cofactor protein (MCP) acts as a cofactor for the cleavage of C4b and C3b by FI. Another cell-surface protein, complement receptor 1 (CR1) inactivates CP and AP convertases, causing dissociation and acting as a FI cofactor. On the other hand, the AP possesses a protein that stabilizes the C3 and C5 convertases, named Properdin (P), the only positive complement regulatory protein described so far ([@B128]). This protein is also a danger recognition module for pathogens such as *Chlamydia pneumonia* ([@B25]) and *Neisseria gonorrhoeae* ([@B132]).

Other complement regulatory proteins, present in the fluid-phase and on membranes, tightly regulate MAC formation. The fluid-phase C5b-7 complex is a target for S-protein and clusterin, abundant serum proteins. On the membrane, CD59 binds to C8 in the C5b-8 complex and blocks the incorporation of C9, preventing MAC formation ([@B81]; [@B29]; [@B99]).

All three complement pathways can be activated in the absence of antibodies, and so the complement system acts as the first barrier preventing infection. However, certain microorganisms have developed mechanisms to escape attack and survive in the host bloodstream ([@B60]). Thus, particular pathogens possess complement regulatory proteins on their surfaces or recruit them from host plasma, as a strategy to resist the complement activation. In *T. cruzi*, several complement regulatory proteins have been described. Some of them have been known for many years ([@B144]) while others have recently been revealed.

Different Stages and Strains of *T. cruzi* Present Variable Susceptibility to the Complement System
===================================================================================================

During its life-cycle, *T. cruzi* experiences multiple regulated morphological and physiological modifications to survive within the triatomine vector and mammalian host cells. Thus, bloodstream trypomastigotes (infective form in mammalian host), amastigotes (intracellular replicative stage in host cells) and metacyclic trypomastigotes (infective forms present in the vector's feces) resist the complement-mediated lysis and the macrophage defense mechanisms. Differently from trypomastigotes, epimastigotes, the replicative and non-infective form of the parasite, present in the mid-gut of triatomine vectors, are highly susceptible to the complement-mediated lysis and cellular destruction ([@B100]; [@B120]; [@B19]).

Early experiments indicated that mice infected with virulent bloodstream trypomastigotes present a marked exacerbation of *T. cruzi* infection with higher parasitemia and mortality when the complement system is depleted with cobra venom factor ([@B15]). This finding indicates that complement is important to control the acute infection. The complement system may cause lysis by activation of the cascade or facilitate the parasite destruction by phagocytic cells. Infective forms of *T. cruzi* (trypomastigotes) in the presence of specific antibodies plus complement, show a certain proportion of surviving parasites ([@B74]). In an attempt to select a trypomastigote subpopulation with increased resistance to lysis by specific antibodies plus complement, the parasites sensitive to immune lysis were eliminated by three successive passages in mice. The resulting parasites maintained their level of sensitivity and produced similar levels of parasitemia ([@B74]). This finding indicates that the complement resistance is more dependent on phenotypic than genetic variations. In other words, it is likely that the number of complement regulatory proteins on the parasite surface follows a phenotypic normal distribution, and this will affect their complement system susceptibility. Consequently, the ability to resist the complement differs not only among different *T. cruzi* strains ([@B19]), but also among individuals in the same strain. Thus, the Colombiana (TcI) strain is more susceptible than the Y strain (TcII). Lysis is apparently due to the CP and LP in early stages of activation ([@B19]).

The role of complement in *T. cruzi* immune lysis has been studied for a long time. This susceptibility varies considerably, among other factors, with the parasite developmental stage ([@B10]). During its cycle in the insect, *T. cruzi* assumes various forms and its infectivity is associated with the acquisition of resistance factors ([@B60]). As previously mentioned, while metacyclic and bloodstream trypomastigotes are resistant, the epimastigotes are extremely sensitive to the complement system ([@B100]; [@B120]). Amastigotes, the replicative form of the parasite, are not exclusively intracellular, being found in the bloodstream during the infection acute stages ([@B85]). In circulation, amastigotes are extremely efficient activators of the complement system cascade, binding the terminal components (C9 polymerization). Although this parasite stage activates the AP, lysis does not occur because the C5b-9 complexes bind but do not insert into the lipid bilayer of the plasma membrane ([@B60]). This kind of activation in the absence of final lysis also occurs in other parasites such as promastigotes of *Leishmania,* which activate the complement system, but with a minimal surface deposition of C9 ([@B113]). Bacteria such as *Borrelia burgdorferi* produce an 80 kDa CD59-like protein, which has affinity for C8β subunit and C9, and prevent MAC formation ([@B110]; [@B83]). A possible explanation of amastigote resistance to the complement system is that hydrophobic domains present on parasite surface molecules serve as non-specific "traps" for nascent C5b-7 complexes that will inefficiently bind C8 and C9. Another possible explanation is the presence of an unidentified specific inhibitor, homologous to a host factor that will prevent the incorporation of C8 and C9 on amastigotes ([@B60]). This resistance, both in trypomastigotes and amastigotes, involves the expression of surface and soluble components playing a role in complement activation.

Complement Regulatory Proteins Expressed on *T. cruzi* Trypomastigotes
======================================================================

Several molecules present on the parasite mediate resistance at different levels of the complement system cascade. In addition, trypomastigotes capture inhibitory host components, which are used to inhibit complement activation on the parasite surface, such as: PMV (**Figure [1A](#F1){ref-type="fig"}**) ([@B18]), TcCRT (**Figures [1B,C](#F1){ref-type="fig"}**) ([@B42]), *T. cruzi* trypomastigote-decay accelerating factor (T-DAF) (**Figure [1D](#F1){ref-type="fig"}**) ([@B76]; [@B136]), *T. cruzi* complement regulatory protein (TcCRP) (**Figure [1E](#F1){ref-type="fig"}**) ([@B104]; [@B105]; [@B13]); FH (**Figure [1F](#F1){ref-type="fig"}**) ([@B124]), gp58/68 (**Figure [1G](#F1){ref-type="fig"}**) ([@B43]) and C2 receptor inhibitor trispanning (CRIT) (**Figure [1H](#F1){ref-type="fig"}**) ([@B19]). The molecular inhibitory mechanisms of these proteins are only partially known for some of these molecules, but the central role is in the inhibition (decay) of C3 and/or C5 convertases. The inhibition of these key enzymes may have important biological consequences, such as: (i) inhibition of complement-mediated lysis, (ii) decrease in C3a and C5a (anaphylatoxins) generation (these small complement fragments are essential in the recruitment of blood cells to the infection site), and (iii) decreased opsonization, which mediates phagocytosis of pathogens during the infection ([@B18]).

![Major strategies involved in host complement system evasion by *T. cruzi*. The three complement pathways are inhibited by *T. cruzi* trypomastigotes. CP inhibition: **(A)** plasma membrane derived vesicles (PMV), inactivating the C3 convertase; **(B,C)** TcCRT, binding to C1q, C1r and C1s and inactivates the C1 complex; **(D)** T-DAF and **(E)** TcCRP, inactivating the C3 convertase. AP inactivation: **(D)** T-DAF, **(E)** TcCRP, **(F)** FH and **(G)** gp 58/68, inhibiting the C3 convertase formation. LP inhibition: **(A)** PMV, inactivating the C3 convertase; **(B)** TcCRT, binding to MBL and L-Ficolin and **(H)** CRIT, binding and inactivating C2.](fmicb-08-01667-g001){#F1}

Trypomastigote Decay-Accelerating Factor (T-DAF)
------------------------------------------------

Human DAF, a 70 kDa glycophospholipid-anchored membrane protein that regulates the CP and AP C3 and C5 convertases, is present on human erythrocytes, neutrophils, lymphocytes, monocytes, platelets and ECs, protecting them from autologous complement ([@B48]).

*Trypanosoma cruzi* trypomastigotes (metacyclic, bloodstream and tissue culture-derived), but not epimastigotes, express a surface glycoprotein of 87--93 kDa, with decay accelerating activity, named trypomastigote-decay accelerating factor (T-DAF) ([@B76]; [@B136]). T-DAF interferes with the efficient assembly of the C3 and C5 convertases of both CP and AP (**Figure [1D](#F1){ref-type="fig"}**), and it is functionally analogous to human DAF ([@B136]). Patients chronically infected with *T. cruzi* have antibodies against this protein ([@B66]; [@B137]). The isolation of a partial cDNA clone of T-DAF and its deduced protein sequence showed 40% homology with a portion of the coding region for human DAF ([@B136]). Human DAF activity is species restricted, while T-DAF protects the parasite against complement system from different mammal species ([@B136]).

*Trypanosoma cruzi* Complement Regulatory Protein (TcCRP)
---------------------------------------------------------

*Trypanosoma cruzi* Complement Regulatory Protein (TcCRP) also named gp160, is a surface-anchored glycoprotein which inhibits the CP and AP (**Figure [1E](#F1){ref-type="fig"}**). TcCRP is expressed by trypomastigotes, but not by epimastigotes ([@B104]). However, stable TcCRP-transfected epimastigotes are protected from complement-mediated lysis, suggesting that epimastigote TcCRP expression is sufficient to confer a virulence-associated trait ([@B103]). First, TcCRP was purified as a 160 kDa glycoprotein present on trypomastigotes with complement regulatory activity. TcCRP binds C3b and C4b ([@B104]; [@B105]; [@B103]) and inhibits the CP and AP C3 convertase formation. This protein is anchored to the trypomastigote membrane via a glycosyl phosphatidylinositol linkage similar to human DAF, but with only two possible SCR and significant DNA sequence identity with human DAF. This protein is a member of the C4/C5 binding family of complement regulatory proteins. Apparently, TcCRP has a decay accelerating activity (inhibiting the C3 convertase), but is not a cofactor for FI (cofactor activity) ([@B104]).

The *T. cruzi* genome contains multiple copies of TcCRPs, and proteins encoded by these genes share sequence similarity with members of the *T. cruzi*-TS superfamily. Since *T. cruzi* requires sialic acid to survive in the mammalian milieu, TS, parasite proteins with enzymatic capacity, transfer monosaccharide from host sialyl-glycoconjugates to terminal β-galactoses of acceptor molecules located on its own surface. These proteins display a variety of biological functions, many of them independent of their enzymatic activities, which promote the evasion of immune response ([@B112]; [@B46]). The TS- superfamily is classified by genomic analysis in eight groups, where only group-I has enzymatic activity, and groups II-VIII are considered inactive ([@B47]). Within the TS superfamily, TcCRP belongs to a subfamily that lack TS activity ([@B14]). Recently, a positive correlation between the virulence of *T. cruzi* strains and TcCRP expression levels has been described ([@B57]).

*Trypanosoma cruzi* Complement C2 Receptor Inhibitor Trispanning Protein (CRIT)
-------------------------------------------------------------------------------

First discovered in *Schistosoma* and humans, CRIT is a 32 kDa protein, containing a 27 amino acid extracellular domain, highly similar to the C4β-chain ([@B63]; [@B62]; [@B61]). This protein is a C2 receptor present on *T. cruzi* and inhibits C2 cleavage by C1s (**Figure [1H](#F1){ref-type="fig"}**) ([@B62]).

C2 Receptor Inhibitor Trispanning Protein (CRIT) from the trypomastigote Y strain binds to and inactivates C2 ([@B19]). *T. cruzi* activates the LP, where a rapid binding of MBL, H-Ficolin, and [L]{.smallcaps}-Ficolin to the surface of *T. cruzi* is detected ([@B19]). In addition, complement sensitive epimastigotes, activate the LP, with MBL, [L]{.smallcaps}-Ficolins and H-Ficolins binding. These components plus C2 and C4 are required for the epimastigote-mediated lysis ([@B20]). MBL, Ficolins and the MASP-2 enzyme bind to metacyclic trypomastigotes in early stages of complement activation ([@B20]). How MBL binds to and interacts with trypomastigotes is still unknown ([@B20]). However, trypomastigotes that express CRIT inhibit LP activation and complement-mediated killing ([@B19]). Transgenic parasites overexpressing CRIT are highly resistant to complement-mediated lysis ([@B20]), where a specific CRIT extracellular domain 1 inhibits the C2 cleavage by MASP2 and impairs C3 convertase formation ([@B20]).

CRIT is expressed in different parasite strains ([@B19]). The gene sequences from other strains such as Cl Brenner, Colombiana and Dm28c are highly similar (88, 90, and 98% identity, respectively) ([@B19]), indicating related function in these strains. However, apparently the CRIT gene is only functional in some *T. cruzi* linages. Thus, when a TcII strain is transfected with the CRIT gene from a TcI strain, the susceptible strain TcII becomes more resistant to the complement-mediated lysis ([@B19]).

Glycoprotein 58/68
------------------

Gp 58/68 is a 58 kDa glycoprotein (as assessed by SDS-PAGE in unreduced condition and 68 kDa, in a reduced condition) present on trypomastigotes ([@B146]). Gp58/68 inhibits the AP C3 convertase (decay-accelerating activity) (**Figure [1G](#F1){ref-type="fig"}**). However, unlike other complement regulatory proteins, such as T-DAF and FH, gp58/68 does not have cofactor activity ([@B43]).

A Fluid-Phase Host Complement Regulatory Proteins, FH, Is Used by *T. cruzi* to Evade Complement Activation
===========================================================================================================

Trypomastigotes cover their surface with sialic acid residues taken from the host by TS ([@B44]). Sialylated molecules downregulate AP activation ([@B109]; [@B158]). FH, the AP negative regulatory protein, could also play a role on parasite complement resistance. FH is composed of 20 SCR domains ([@B108]) with different functions. FH possesses three sites ([@B126]) that interact with unique domains on C3b ([@B8]; [@B82]; [@B126]; [@B67]), participating in: (i) decay-accelerating activity for the AP C3/C5 convertases, (ii) cofactor for FI activity, and (iii) interaction with sialic acids ([@B7]; [@B80]; [@B108]). *T. cruzi* possesses TS to transfer α(2-3)-linked sialic acid from serum glycoconjugates to acceptor sites on the parasite surface ([@B125]; [@B143]). These glycoconjugates restrict complement activation on the microbes surface, and are considered a virulence factor ([@B33]; [@B94]; [@B153]; [@B34]). This polyanion on the trypomastigote surface may also be critical for parasite survival in the circulation ([@B75]; [@B127]). In parallel, FH binds to *T. cruzi*, with higher affinity to metacyclic trypomastigotes than to epimastigotes ([@B124]). Since, FH binds to trypomastigotes covered by sialic acid via TS action, it could participate as an important complement regulatory protein to control the AP activation (**Figure [1F](#F1){ref-type="fig"}**).

Plasma Membrane-Derived Vesicles (PMVs) and *T. cruzi* Exosomes
===============================================================

Plasma membrane-derived vesicles play important roles in several infectious- and non-infectious diseases and stress ([@B24], [@B23]; [@B6]; [@B12]; [@B40]; [@B9]). Bloodstream and ECs release PMV from their cellular membranes ([@B51]; [@B111]; [@B22]; [@B9]). *T. cruzi* trypomastigotes are exposed to PMVs from several cell types. *T. cruzi* induces an increase in PMV released from blood cells in a Ca^2+^-dependent manner. *T. cruzi* surface molecules such as gp82 and oligopeptidase B induce a transient increase of intracellular Ca^2+^ in host cells, which could induce PMV release. These vesicles bind to C3 convertase, inhibiting its catalytic activity of both CP and LP (**Figure [1A](#F1){ref-type="fig"}**). The molecules on the PMVs interacting with C3 convertases are still unknown ([@B18]). On the other hand, TGF-β-bearing PMVs promote host cell invasion via the lysosome-independent route. This phenomenon is dose- and parasite- infective stage dependent and non-specific for parasite strains or host cell types ([@B18]). In agreement with this TGF-β function, chronically infected patients have higher levels of circulating TGF-β ([@B11]). Thus, TGF-β-bearing PMVs could activate the TGF-β signaling pathway to promote parasite infectivity ([@B18]). Similar PMVs-mediated mechanisms have been described to other infectious agents such as HIV ([@B91]) and *Plasmodium* sp. ([@B40]). At the same time, *T. cruzi* produces exosomes that stimulate different host cells to produce PVMs to modulate the host immune response ([@B18]; [@B93]). The *T. cruzi* exosomes contain several surface components, like glycoproteins, such as gp85/transialidases, alphaGal-containing molecules, proteases, cytoskeleton proteins, mucins, and associated to GPI-anchored molecules.

*Trypanosoma cruzi* Calreticulin, an Important Virulence Factor
===============================================================

Our laboratory has been working for over 20 years with TcCRT, a multifunctional ER-resident protein that the parasite translocates to the external milieu, mainly via the area of flagellum emergence. Although TcCRT is located mainly in the ER, histochemical studies have found it also in the Golgi, reservosomes, flagellar pocket, cell surface, cytosol, nucleus and kinetoplast ([@B42]; [@B131]; [@B53]). However, the mechanisms involved in these heterogeneous TcCRT locations are still unknown.

Similar to its human counterpart HuCRT, TcCRT is a key protein for *T. cruzi*. Thus, epimastigotes bearing a monoallelic deletion of the TcCRT gene present a reduced rate of differentiation to trypomastigotes in an *in vitro* assay ([@B122]).

In spite of the long evolutionary distance, TcCRT shares 50% homology with HuCRT ([@B114]), a molecule with more than 40 functions described ([@B35]). HuCRT has three domains: globular N-terminus (N), proline-rich (P), and acidic C-terminus ([@B95]). An S-domain (aa 160--283), within N and P, interacts with C1q ([@B134], [@B133]), the first component of the CP. TcCRT shares these domains and is involved in a variety of host-pathogen interactions, such as immune evasion, *T. cruzi* infectivity and tumor growth inhibition (**Figure [2](#F2){ref-type="fig"}**).

![TcCRT participates in three important mechanisms related to *T. cruzi* infection. **(A)** TcCRT, translocated and secreted by the parasite, binds to C1 or MBL or [L]{.smallcaps}-Ficolin inactivating the CP and LP of complement system. **(B)** TcCRT binds C1 on the area of flagellar emergence. The TcCRT/C1q complex is recognized by CRT on the host cell surface (cC1qR), promoting host cell infectivity. **(C)** TcCRT has anti-angiogenic and anti-tumor growth properties.](fmicb-08-01667-g002){#F2}

TcCRT Participates in the Inhibition of *T. cruzi* Complement-Activation
------------------------------------------------------------------------

*Trypanosoma cruzi* inhibits the early stages of CP activation. Previous reports indicate that the CP is activated inefficiently on *T. cruzi* and it is rendered more efficient in the presence of specific lytic antibodies present in *T. cruzi* seropositive individuals ([@B3],[@B4],[@B5]). Other studies indicate that the CP participates as an enhancer for the AP in *T. cruzi* complement activation because C2 depletion or CP inhibition (using EGTA) do not affect significantly the parasite complement-mediated lysis ([@B79]). The LP has a key role in host defense. Mutations in LP main components, MBL, Ficolins and MASPs, increase susceptibility to several infectious diseases ([@B59]; [@B37]). The LP is activated on *T. cruzi*. This parasite binds MBL, *H*-Ficolin and [L]{.smallcaps}-Ficolin and serum depleted of these molecules failed to destroy the parasites ([@B20]). LP activation also triggers AP activation by C3b generation. This synergic effect enhances the complement-lysis capacity ([@B20]). One report, however, indicates that MASP-2 full deficiency in KO mice, does not increase mice susceptibility to *T. cruzi* ([@B118]).

In this context, our laboratory has shown that TcCRT is involved in several key aspects of the host/parasite interplay, such as inhibition of both the CP and LP. TcCRT inhibits the CP, interacting with C1 (**Figures [1B](#F1){ref-type="fig"}**, **[2A](#F2){ref-type="fig"}**). This interaction inactivates the CP at the earliest stages. TcCRT binds to the collagenous tails of C1q interfering with the activation of C1s and subsequent C1s-mediated cleavage of C4 and, as a consequence, inhibiting the entire cascade ([@B42]). The capacity to bind C1q and inhibit complement resides in the central TcCRT S-domain (aa 159--281). TcCRT competes with the (C1r-C1s)~2~ tetrameric complex to bind C1q, decreasing C4b generation and, as a consequence, the levels of the CP C3 and C5 convertases generated ([@B42]). The TcCRT capacity to bind C1q and to inhibit C4b generation is calcium-independent ([@B145]). In addition to C1q, both CP serine-proteases, C1s and C1r, bind TcCRT *in vitro*. However, TcCRT does not inhibit the C4-activating function of solid phase-bound C1s. Perhaps, C1s inactivation occurs only when the serine protease is part of C1 complex \[C1q, (C1r, C1s)~2~\] ([@B145]). Additionally, TcCRT competes with the serine proteases, but does not displace them from the preformed C1 complex ([@B145]).

Several functions are shared and conserved to differing degrees by calreticulin (CRT) from different species ([@B114]). Recently, an important domain of *Triatoma infestans* calreticulin (TiCRT), protein present in saliva of this vector, was cloned and expressed. This domain also binds C1, inhibiting the CP. The presence of TiCRT in hematophagous triatomines saliva may control the potential activation of complement in the digestive tract of these vectors and subsequent tissue damage ([@B152]). This function has been studied in other species, such as *Amblyomma americanum*. This tick, while feeding on its host, secretes CRT ([@B64]), presumably as a mechanism to evade or inactivate the host complement system ([@B114]), thus preventing damage to its digestive mucosa.

A recent crystallographic structural study defines CRT conformational rearrangements that could be informative in future therapeutic investigations of parasite CRTs ([@B98]), mainly in its anti-complement and anti-neoplastic effects.

TcCRT also binds MBL and Ficolins, inhibiting the LP (**Figure [1B](#F1){ref-type="fig"}**) ([@B129]). *L*-, *H*- and *M*-Ficolins have been described ([@B38]; [@B89]; [@B135]; [@B138]; [@B155]). *L*- and *H*-Ficolins bind to LTA ([@B90]) and acetylated sialic acids, both cell components found in Gram-positive and -negative bacteria, respectively, with subsequent MASP activation ([@B54]). However, [L]{.smallcaps}-Ficolin (but not *H*-Ficolin) binds to TcCRT, but the TcCRT/L-Ficolin does not interfere with LTA binding to [L]{.smallcaps}-Ficolin, but does interfere with its activation via LTA. Moreover, [L]{.smallcaps}-Ficolin binds preferentially to trypomastigotes, as compared to epimastigotes, which translocate significantly lower amounts of TcCRT to their surfaces ([@B129]). Whether *M*-Ficolin binds is still unknown.

Furthermore, parasites carrying a monoallelic deletion of the *TcCRT* gene, are significantly susceptible to complement-mediated lysis. As expected, parasites overexpressing TcCRT are significantly more resistant to the complement-mediated lysis by CP and LP ([@B122], [@B121]).

TcCRT and Its Role in the *T. cruzi* Infectivity Process
--------------------------------------------------------

CRT is also a membrane receptor for C1q, named cC1qR ([@B36]). This protein participates in the immune response against apoptotic cancer cells, as an *"eat me"* signal required for phagocytosis on dying tumor cells ([@B49]). Apoptotic cells expose CRT on their surfaces, where it is recognized by C1q. The CRT/C1q complex on the parasite is an *"eat me"* signal for phagocytic cells expressing cC1qR ([@B92]).

TcCRT, expressed mainly in the area of parasite flagellum emergence, recruits C1q/C1, in a molecular mimicry strategy. Similar to apoptotic cells, the TcCRT/C1q complex is recognized as an *"eat me"* signal by cC1qR/CRT on phagocytes and other cellular types, thus promoting infectivity (**Figure [2B](#F2){ref-type="fig"}**). As expected, anti-TcCRT F(ab')~2~ antibodies inhibit the TcCRT/C1q interaction and, as a consequence, decrease infectivity *in vitro* and *in vivo* ([@B115]). Additionally, this TcCRT/C1q-mediated infectivity correlates with a significant increase in TcCRT mRNA levels in the early infection steps ([@B115]). Unlike the infective forms, epimastigotes are highly sensitive to the complement activation, most likely due, at least in part, to the marginal levels of TcCRT expressed on their surfaces ([@B42]; [@B1]). However, epimastigotes bind exogenously added TcCRT and are internalized by fibroblasts in a C1q-dependent manner. Likewise, CRT-deficient fibroblasts have impaired capacity to internalize TcCRT, indicating again that the TcCRT/C1/CRT complex participates in the invasion process ([@B130]). Mice inoculated with mutant trypomastigotes (carrying a monoallelic TcCRT deletion gene), do not generate detectable parasitemia, meaning that parasites do not proliferate and therefore no anti-*T. cruzi* IgG antibodies are generated. Thus, these mutants are restricted in two important properties conferred by the TcCRT/C1q interaction: their capacity to evade the CP and LP (**Figure [1B](#F1){ref-type="fig"}**), and their virulence (**Figure [1C](#F1){ref-type="fig"}**) ([@B121]).

This infection strategy is important in the congenital transmission of trypanosoma infection, given its relevance in the epidemiology of this infection, in particular its emergence in developed countries. The human placenta expresses high CRT levels ([@B58]), in particular during pregnancy ([@B55]; [@B26]). Translocated parasite TcCRT, binds and inactivates C1 that will in turn bind the parasite to cC1qR present on the placental ST. This newly formed TcCRT/C1q/CRT synapsis is important to infect the human placenta, as measured in an *ex vivo* model ([@B17]). Thus, a molecular basis that explains at least an important part of the parasite to contact the ST is provided.

TcCRT also binds to MBL and [L]{.smallcaps}-Ficolin ([@B42]; [@B145]), but the role of TcCRT/MBL or [L]{.smallcaps}-Ficolin in *T. cruzi* infectivity process has not yet been addressed. However, a study using two *T. cruzi* strains, susceptible and resistant, suggested that MBL participates in the infectivity process while the parasite deactivates the LP ([@B39]), but the ligand for MBL on the parasite surface is still unknown. Besides the TcCRT interplays with MBL, C1q and [L]{.smallcaps}-Ficolin, additional studies on the possibilities of functional interactions with SP-A, SP-D should be undertaken.

TcCRT Interactions with the Complement System Mediate Tumor Growth Inhibition
-----------------------------------------------------------------------------

For several decades now an antagonism between Chagas' disease and tumor development has been observed. Several *T. cruzi* strains exhibited growth inhibitory properties over transplanted or spontaneous tumors, in murine experimental models and in humans ([@B68]; [@B106]). The molecular mechanisms or particular molecules involved in this process were unknown, although the anti-tumor property was attributed to a "toxic substance," secreted by the parasite, which reduced pain, inflammation, tumor growth and bleeding ([@B119]; [@B56]; [@B77]; [@B78]).

Our laboratory has contributed to elucidate the role of TcCRT as a mediator of at least an important part of this effect. TcCRT is anti-angiogenic *in vitro* ([@B88]), *ex vivo* ([@B142]) and *in vivo* ([@B88]; [@B2]; [@B1]), inhibiting the growth of mammary adenocarcinoma and melanoma in murine models ([@B97]; [@B88]; [@B142]; [@B2]). A recombinant TcCRT and its specific N-terminal domain (aa 120-180) inhibit capillary growth *ex vivo* in *Rattus rattus* aortic rings, morphogenesis, proliferation and chemotaxis in human umbilical cord ECs (HUVEC) ([@B88]) and an *in vivo* angiogenesis model in *Gallus gallus* chorioallantoic membrane assay ([@B97]). Specific anti-TcCRT antibodies inhibit the TcCRT anti-angiogenic effect ([@B142]). This effect is shared with HuCRT. However, TcCRT is approximately 2-fold more efficient at equimolar concentrations ([@B88]; [@B142]). In addition, TcCRT is internalized by ECs. However, this internalization is susceptible to be inhibited by Fucoidan, a ligand for SR ([@B88]), indicating SR as an additional possible receptor to TcCRT on ECs. In addition, the interaction of TcCRT and ECs can be inhibited by anti-TcCRT antibodies or Fucoidan, thus strengthening the participation of SR in this interaction ([@B1]). These antibodies also revert the TcCRT effect on EC proliferation ([@B1]).

TcCRT also inhibits tumor growth. TcCRT inoculated in a peritumoral area reduced, more efficiently than HuCRT, the growth of an aggressive, multi-resistant mammary adenocarcinoma (TA3-MTXR) in an *in vivo* murine model ([@B88]). Indeed, in these experiments HuCRT did not show antitumor effects. Since all these effects were tested using exogenous recombinant TcCRT, we recently verified the effect of native TcCRT (in the context of the parasite) on the tumor growth in infected animal. Thus, mice were inoculated with TA3-MTXR tumor cells and infected with *T. cruzi* trypomastigotes. In parallel, these animals were treated with anti-TcCRT antibodies. As expected, these antibodies, but not their pre-immune counterparts, neutralized the anti-tumor effect of the infection, indicating that native endogenous TcCRT, in the context of the parasite, is responsible for at least an important part of the anti-tumor effect of *T. cruzi* infection ([@B1]). Thus, our model proposes that, native TcCRT (secreted or on the parasite) mediates fundamental alterations in the tumor cell microenvironment leading to an adaptive immune response, with significant anti-tumor consequences.

Once in the bloodstream, trypomastigotes infect ECs by recruiting C1 via externalized TcCRT (**Figures [2A,B](#F2){ref-type="fig"}**). This TcCRT also inhibits angiogenesis (**Figure [2C](#F2){ref-type="fig"}**) and allows the contact with EC via HuCRT \[also known as cC1qR ([@B133])\] or SRs (**Figure [2C](#F2){ref-type="fig"}**). Tumor cell phagocytosis by dendritic cells is stimulated through C1q recruitment (*"eat me"* signal). The evoked adaptive immune response could be stimulated by TcCRT (or HuCRT). Thus, dendritic cells will cross-present antigenic peptides derived from TcCRT (and/or from still unidentified tumor specific antigens-TSAs) to cytotoxic T cells in the draining regional lymph nodes (**Figure [2C](#F2){ref-type="fig"}**). These activated T lymphocytes will return to the tumor site and act against tumor cells ([@B116]). The possible simultaneous role of T helper, NK and NKT cells are matters of current research in our laboratory. Mammal CRTs are about 95% identical among them, while TcCRT differs by 50% in its primary sequence, from these counterparts. Therefore, rTcCRT upon binding to tumor cells, is potentially more suitable than HuCRT to force their immunogenicity ([@B152]).

Conclusion
==========

*Trypanosoma cruzi* has developed different adaptive strategies to avoid destruction by the host immune system, in particular by complement. In many conditions, the parasite has acquired these abilities only at the stage of development that are infective for the host (trypomastigotes and amastigotes). Thus, the non-infective forms of the parasite are susceptible to the complement in the presence of human serum while trypomastigotes are highly resistant. Recently, it has been demonstrated that this resistance varies also between strains. The complement system is a physiological barrier during infection which the infective forms must evade in early stages. These infective forms express on their surfaces different complement regulatory proteins or capture them from the host plasma to inhibit the complement system. Most of these proteins have a decay-accelerating activity, inhibiting the C3 convertase formation (such as T-DAF, CRP, gp58/68 and FH) and/or participate as a cofactor for FI (such as FH). Other components inactivate the catalytic activity of C3 convertase (PMV), or bind and inactivate specific complement components (TcCRT and CRIT). Some of these proteins are multifunctional. Thus, TcCRT disrupts the initial step of CP and LP, reducing the C3 convertase formation. However, TcCRT is also an important virulence factor in association with C1. Thus, the TcCRT/C1 interaction on the parasite surface promotes infectivity *in vitro* and *in vivo.* On the other hand, native endogenous parasite TcCRT inhibits tumor development in infected animals, since this effect is fully reproduced by recombinant TcCRT and reversed by specific antibodies. This role is in agreement with previous reports indicating a possible protective role of *T. cruzi* infection in cancer development.
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AP

:   alternative pathway

C1-INH

:   C1-inhibitor

C4BP

:   C4 binding protein

CP

:   classical pathway

CRIT

:   *T. cruzi* C2 receptor inhibitor trispanning
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:   calreticulin

DAF

:   human decay-accelerating factor

ECs

:   endothelial cells

ER
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:   factor H
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:   factor I
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:   human calreticulin
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:   lectin pathway

LTA

:   lipoteichoic acid

MAC

:   membrane attack complex

MASPs

:   Mannan-binding lectin serine protease

MBL

:   Mannan-binding lectin

PAMPs

:   pathogen associated molecular patterns

PMVs

:   plasma-membrane derived-vesicles

SCR

:   short consensus repeats

SRs

:   scavenger receptors

ST

:   syncytiotrophoblast

TcCRP

:   *Trypanosoma cruzi* complement regulatory protein

TcCRT

:   Trypanosoma cruzi calreticulin

*T-DAF*

:   *Trypanosoma cruzi* trypomastigote decay-accelerating factor

TP

:   terminal pathway

TS

:   *Trans*-sialidase.
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